Long‐term antiviral therapy for recurrent hepatitis C after liver transplantation in nonresponders: Biochemical, virological, and histological impact
Thomas Walter, Jean‐Yves Scoazec, Olivier Guillaud, Valérie Hervieu, Philippe Chevallier, Olivier Boillot, Jérôme Dumortier – 24 December 2008 – More than 50% of patients with a recurrent posttransplant hepatitis C virus infection fail to respond to antiviral treatment. The aim of this study was to evaluate the interest of a long‐term antiviral treatment maintained for more than 48 weeks. Seventy treated patients, with a histological follow‐up > 1 year, were enrolled in this observational, retrospective study.